Selected publications
- Kralovics et al., A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352 (17), 1779-90.
- Klampfl et al., Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013, 369 (25), 2379-90.
- Harutyunyan et al., p53 lesions in leukemic transformation. N Engl J Med 2011, 364 (5), 488-90.
- Olcaydu et al., A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009, 41 (4), 450-54.
- Schischlik et al., Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood 2019, 134(2):199-210.
- Milosevic Feenstra et al., Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood 2016, 127 (3), 325-32.
- Nivarthi et al., Thrombopoietin receptor is required for the oncogenic function of CALR mutants. Leukemia 2016, 30 (8), 1759-63.
- Vainchenker & Kralovics, Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 2017, 129 (6), 667-679.
- Harutyunyan et al., Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood 2016, 127 (3), 362-5.
- Klampfl et al., Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011, 118 (1), 167-76.